Ozempic vs Wegovy in New Zealand — What is the Difference? | KiwiMeds
✅ Reviewed by Ramon Wong, BPharm, Registered Pharmacist (New Zealand) | May 2026 — This information is for educational purposes only and is not a substitute for personalised advice from your doctor or pharmacist. Always seek professional guidance before making changes to your medications.
Ozempic and Wegovy both contain semaglutide — the same active ingredient. The key difference is the dose and what they’re approved for. Understanding this distinction is essential for New Zealanders navigating treatment for type 2 diabetes or obesity.
What are Ozempic and Wegovy?
- Ozempic — semaglutide injection approved for type 2 diabetes; doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg weekly
- Wegovy — semaglutide injection approved for chronic weight management (obesity); dose of 2.4 mg weekly
Both are manufactured by Novo Nordisk and given as a once-weekly subcutaneous injection. The difference is simply the licensed indication and maximum dose.
Ozempic vs Wegovy — key differences at a glance
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Approved for | Type 2 diabetes | Obesity / weight management |
| Doses available | 0.25, 0.5, 1, 2 mg/week | Up to 2.4 mg/week |
| Funded by Pharmac (NZ)? | ✅ Yes — with criteria | ❌ No |
| Average weight loss | ~5–10% body weight | ~12–15% body weight |
| Pen device | Ozempic pen | Wegovy pen (different) |
How semaglutide works
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a gut hormone that:
- Stimulates insulin release in response to meals
- Reduces glucagon (which would otherwise raise blood sugar)
- Slows the rate at which food leaves the stomach
- Acts on the brain to reduce appetite and increase feelings of fullness
At the higher dose used in Wegovy (2.4 mg), the appetite-suppressing effect is stronger, which explains the greater weight loss compared to the diabetes doses used in Ozempic.
Is Ozempic funded in New Zealand?
Yes — with conditions. Pharmac funds Ozempic (semaglutide) for people with type 2 diabetes who meet Special Authority criteria, which include:
- Established type 2 diabetes
- HbA1c not adequately controlled on metformin and/or other funded oral agents
- BMI criteria may apply
- Prescription by or on advice from an appropriate specialist (criteria may vary)
If you have type 2 diabetes and your doctor thinks semaglutide is appropriate, you may qualify for funded Ozempic. Check the current Pharmac Schedule for exact criteria, as they can change.
Is Wegovy funded in New Zealand?
No. As of May 2026, Wegovy (the obesity-dose version) is not funded by Pharmac in New Zealand. If prescribed for weight management without a diabetes diagnosis, patients pay full private cost — typically around $450–$600 per month for the 2.4 mg dose.
Can I use Ozempic for weight loss in NZ?
This is a common question. Technically, some doctors may prescribe Ozempic at its higher doses (up to 2 mg) for weight loss in people without diabetes — this is “off-label” prescribing, which is legal in NZ. However:
- Without a diabetes diagnosis, Ozempic will not be funded by Pharmac
- The maximum dose of Ozempic is 2 mg, compared to 2.4 mg for Wegovy — this means slightly less weight loss on average
- For dedicated obesity treatment, Wegovy (2.4 mg) or tirzepatide (Mounjaro) may be more appropriate clinically
Ozempic vs Wegovy — side effects
Because the same molecule is involved, the side effect profiles are very similar:
- Very common: Nausea, vomiting, diarrhoea, constipation — most common when starting or increasing dose
- Common: Decreased appetite, abdominal pain, injection site reactions, headache, fatigue
- Serious (rare): Pancreatitis, thyroid tumours (animal data only), diabetic retinopathy, kidney problems, severe hypoglycaemia (with insulin or sulfonylurea)
The higher dose in Wegovy means nausea and gastrointestinal side effects may be more pronounced for some people, but the dose is increased gradually to improve tolerability.
Which is better — Ozempic or Wegovy?
The right choice depends on your situation:
- If you have type 2 diabetes: Ozempic is likely the appropriate choice, and you may qualify for Pharmac funding. The medication manages both blood sugar and weight simultaneously.
- If you have obesity without diabetes: Wegovy (2.4 mg semaglutide) or tirzepatide (Mounjaro) would be clinically more appropriate for maximum weight loss — but neither is funded in NZ.
- Cost perspective: Funded Ozempic for type 2 diabetes patients costs only the standard Pharmac co-payment (currently $5 per prescription). Private Wegovy costs hundreds of dollars per month.
Ozempic vs Mounjaro (tirzepatide) — which is more effective?
For both blood sugar control and weight loss, tirzepatide (Mounjaro) produces greater average results than semaglutide in head-to-head trials. The SURMOUNT-5 trial showed approximately 20% weight loss with tirzepatide vs 14% with semaglutide. However, tirzepatide is more expensive and not funded. Individual responses vary — some people do better on semaglutide.
Read our Tirzepatide (Mounjaro) NZ Guide →
Frequently asked questions
Can my doctor switch me from Ozempic to Wegovy?
Yes — both contain the same molecule. Your doctor can transition you to Wegovy if you are seeking higher-dose semaglutide for weight management, though you will pay privately if you don’t have a qualifying diabetes diagnosis.
Is there a semaglutide tablet in NZ?
Rybelsus is an oral semaglutide tablet approved for type 2 diabetes. It is available in NZ on prescription but is not on the Pharmac Schedule as of May 2026.
Are there supply shortages of Ozempic or Wegovy in NZ?
Semaglutide products have experienced significant international supply pressures due to high demand. Availability can vary — your pharmacist can advise on current stock at time of dispensing.
📬 Get Pharmac updates by email — Join the free KiwiMeds Bulletin for any changes to semaglutide funding in NZ. Subscribe free →